M Schmidt-Hieber1, A Busse, B Reufi, W Knauf, E Thiel, I W Blau. 1. Medizinische Klinik III (Hämatologie, Onkologie und Transfusionsmedizin), Charité, Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany. martin.schmidt-hieber@charite.de
Abstract
PURPOSE: We investigated the in vitro toxicity of bendamustine and fludarabine to hematopoietic progenitors and stem cells from healthy donors. METHODS: Clonogenic agar colony assays, non-clonogenic long-term liquid cultures (LTC) and apoptosis assays were used to assess the cytotoxicity of both the agents. RESULTS: Total colony-forming units (CFU) were more sensitive to fludarabine than to bendamustine in agar colony assays (IC(50) 0.7 microM/L and 8.5 microM/L, respectively). Using the Bliss independence model and combining the two agents yielded additive inhibition of progenitors. Non-clonogenic assays, including LTC and an apoptosis assay detecting activated caspases showed that stem cells are characterized by low sensitivity to bendamustine. In contrast, fludarabine strongly inhibited the viability and growth of stem cells in LTC. CONCLUSIONS: Our data show that bendamustine is characterized by lower in vitro toxicity to hematopoietic progenitors and stem cells than fludarabine and might thus be preferable in regimens prior to stem cells apheresis.
PURPOSE: We investigated the in vitro toxicity of bendamustine and fludarabine to hematopoietic progenitors and stem cells from healthy donors. METHODS: Clonogenic agar colony assays, non-clonogenic long-term liquid cultures (LTC) and apoptosis assays were used to assess the cytotoxicity of both the agents. RESULTS: Total colony-forming units (CFU) were more sensitive to fludarabine than to bendamustine in agar colony assays (IC(50) 0.7 microM/L and 8.5 microM/L, respectively). Using the Bliss independence model and combining the two agents yielded additive inhibition of progenitors. Non-clonogenic assays, including LTC and an apoptosis assay detecting activated caspases showed that stem cells are characterized by low sensitivity to bendamustine. In contrast, fludarabine strongly inhibited the viability and growth of stem cells in LTC. CONCLUSIONS: Our data show that bendamustine is characterized by lower in vitro toxicity to hematopoietic progenitors and stem cells than fludarabine and might thus be preferable in regimens prior to stem cells apheresis.
Authors: M Schmidt-Hieber; I W Blau; R Trenschel; R Andreesen; G Stuhler; H Einsele; L Kanz; U Keilholz; O Marinets; D W Beelen; A A Fauser; L Volin; T Ruutu; L Uharek; T Fietz; W Knauf; W Hopfenmüller; E Thiel; M Freund; J Casper Journal: Bone Marrow Transplant Date: 2007-02-19 Impact factor: 5.483
Authors: G Perea; A Sureda; R Martino; A Altés; C Martínez; E Cabezudo; B Amill; G A Martín-Henao; Y González; L Muñoz; M Peyret; S Brunet; J Sierra Journal: Ann Hematol Date: 2001-10 Impact factor: 3.673
Authors: J M Foran; D Oscier; J Orchard; S A Johnson; M Tighe; M H Cullen; P G de Takats; C Kraus; M Klein; T A Lister Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544
Authors: S Gupta; P Zhou; H Hassoun; T Kewalramani; L Reich; S Costello; L Drake; V Klimek; M Dhodapkar; J Teruya-Feldstein; C Hedvat; N Kalakonda; M Fleisher; D Filippa; J Qin; S D Nimer; R L Comenzo Journal: Bone Marrow Transplant Date: 2005-03 Impact factor: 5.483
Authors: Linda E Bröker; Cynthia Huisman; Carlos G Ferreira; José A Rodriguez; Frank A E Kruyt; Giuseppe Giaccone Journal: Cancer Res Date: 2002-07-15 Impact factor: 12.701
Authors: M Rasschaert; D Schrijvers; J Van den Brande; J Dyck; J Bosmans; K Merkle; J B Vermorken Journal: Br J Cancer Date: 2007-05-08 Impact factor: 7.640
Authors: Martin Schmidt-Hieber; Robert Dabrowski; Babette Aicher; Philipp Lohneis; Antonia Busse; Carola Tietze-Buerger; Birgit Reufi; Eckhard Thiel; Igor Wolfgang Blau Journal: Invest New Drugs Date: 2011-07-13 Impact factor: 3.850
Authors: Martin Schmidt-Hieber; Robert Dabrowski; Andreas Weimann; Babette Aicher; Philipp Lohneis; Antonia Busse; Eckhard Thiel; Igor W Blau Journal: Invest New Drugs Date: 2010-11-16 Impact factor: 3.850
Authors: M Kaiser; A Kühnl; J Reins; S Fischer; J Ortiz-Tanchez; C Schlee; L H Mochmann; S Heesch; O Benlasfer; W-K Hofmann; E Thiel; C D Baldus Journal: Blood Cancer J Date: 2011-07-15 Impact factor: 11.037
Authors: D J Green; W I Bensinger; L A Holmberg; T Gooley; B G Till; L E Budde; J M Pagel; S L Frayo; J E Roden; L Hedin; O W Press; A K Gopal Journal: Bone Marrow Transplant Date: 2016-05-23 Impact factor: 5.483